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ABSTRACT
This paper describes the development and in vitro evaluation of poly(lactic-co-glycolic acid) (PLGA)
nanoparticles coated with chitosan (CS) for oral delivery of ferulic acid (FA). Nanoparticles were
obtained by an emulsion evaporation technique and characterized. Furthermore, we evaluated the scav-
enging activity over hypochlorous acid (HOCl), the cytotoxicity over tumour cells and the in vitro intes-
tinal permeability. Nanoparticles were spherical with a mean diameter of 242nm, positive zeta potential
and 50% of encapsulation efficiency. The in vitro release in phosphate buffered saline (PBS) (pH 7.4)
demonstrated a prolonged and biphasic profile diffusion-controlled. In simulated gastrointestinal fluids,
about 15% of FA was released in gastric fluid and a negligible release was observed in the intestinal
fluid. In the HOCl scavenging activity and cytotoxicity over B16-F10 and HeLa cells, FA-loaded nanopar-
ticles presented the same efficacy of the free drug. Besides, in the antioxidant and cytotoxic assay,
CS contributed to FA effects. In the intestinal permeability study, FA-loaded nanoparticles exhibited
a permeation of 6% through the Caco-2 monolayer and 20% through the Caco-2/HT29-MTX/Raji B
co-culture. CS-coated PLGA nanoparticles are promising carriers for oral delivery of FA.
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Introduction
Ferulic acid (FA) is a polyphenol present in fruits, vegetables
and some beverages (such as coffee and beer), which has
high antioxidant activity, acting as a free radical scavenger
[1]. Its antioxidant action is due to its unsaturated side chain
and to the phenolic nucleus, which allows the spontaneous
stabilization of structures by resonance. Furthermore, studies
have shown that FA presents antitumour, anti-inflammatory,
hepatoprotective, vasodilatory, antithrombotic, antiallergic,
antiviral, antimicrobial and photoprotective activity. Most of
these pharmacological effects are results of the antioxidant
activity of FA [2]. It is well known for the role of reactive oxy-
gen species (ROS) in lipid peroxidation, enzyme oxidation
and massive protein degradation and oxidation. Effects as cell
degradation, DNA damage and carcinogenesis can be caused
by excessive ROS and they can trigger a variety of diseases
and disorders, such as aging, cancer, hypertension, cardiac
and neurodegenerative diseases, rheumatoid arthritis, dia-
betes mellitus and atherosclerosis [3]. Thus, the study and
search for antioxidants that can restrain radicals and slow the
progress of chronic diseases are essential [4]. However, the
potential of FA, due to its low solubility and permeability, FA
absorption from the gastrointestinal tract (GIT) is limited
when administered by conventional oral dosage forms, such
as tablets and granules, hindering its efficacy [5]. Some micro
and nanotechnological approaches have been done to
improve the physicochemical, biopharmaceutical and phar-
macokinetic of FA, thus increasing its bioavailability [5–8].
The application of nanoparticles in drug delivery is an
important tool to circumvent physicochemical and bio-
pharmaceutical drug drawbacks and improve drug bioavail-
ability. Nanoparticles can permeate interstitial spaces
enhancing the cellular uptake of the drug [9].
Poly(lactic-co-glycolic acid) (PLGA) is a copolymer widely
used as a matrix for nanoparticles due to its biocompatible
and biodegradable characteristics [10]. Chitosan (CS) is a nat-
ural, biodegradable and biocompatible polysaccharide
derived from total or partial deacetylation of chitin [11]. Its
mucoadhesive property, when positively charged, allows the
interaction with negatively charged membranes and mucosa,
promoting a greater interaction, adhesion and retention of
the pharmaceutical form-containing CS close to the intestinal
epithelium [12]. In addition, CS has the ability to temporarily
open the tight junctions of the intestinal epithelium, thereby
increasing the drug permeability [13].
In this work, PLGA nanoparticles coated with CS contain-
ing FA for oral delivery were developed, characterized and
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in vitro evaluated for the antioxidant activity, cytotoxicity
over tumour cells lines (B16-F10 and HeLa). Also, the nano-
particles permeability through Caco-2 monolayer and Caco-2/
HT29-MTX/Raji B co-culture was carried out.
Materials and methods
Materials and reagents
3,30,5,50-Tetramethylbenzidine (TMB), ferulic acid (FA; 99%),
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), glucose, Dulbecco’s modified Iscove’s medium, pan-
creatin of porcine pancreas (P1625), porcine gastric
mucosal pepsin (P7125), polyvinyl alcohol (PVA; 31 KDa, 88%
hydrolysed), poly(lactic-co-glycolic acid) (PLGA; 65:35,
40000–75000Da) and chitosan (CS; Medium molecular
weight, 75–85% deacetylated) were purchased from Sigma-
Aldrich (St. Louis, MO). Isopropyl alcohol, dichloromethane
and ethanol (95%) were purchased from Fmaia (Cotia, Brazil).
Sodium chloride, dibasic sodium phosphate, sodium hydrox-
ide and hydrogen peroxide (30%) were purchased from
Biotec (S~ao Paulo, Brazil). HPLC grade acetonitrile was
obtained from LiChrosolv-Merck (Darmstadt, Germany).
Sodium heparin was purchased from Hipolabor (Sabara,
Brazil). Hank’s Balanced Salt Solution (HBSS) and tripsin were
purchased from Gibco (Carlsbad, CA). Streptomycin and peni-
cillin were purchased from Sigma Aldrich (St. Louis, MO) and
Invitrogen Corporation (Life Technologies, S.A., Madrid,
Spain). Fetal bovine serum was obtained from Gibco. Non-
essential amino acids (NEAA) were purchased from Invitrogen
Corporation (Life Technologies, S.A., Madrid, Spain). Triton X-
100 was purchased from Spi-Chem (West Chester, PA).
Dulbecco’s modified Eagle medium was obtained from Lonza
(Verviers, Belgium). B16-F10, HeLa, C2BBe1 clone of Caco-2
was obtained from American Type Culture Collection (ATCC,
Manassas, VA), HT29-MTX and Raji B were provided by Dr. T.
Lesuffleur (INSERMU178, Villejuif, France) and by Dr.
Alexandre Carmo (Cellular and Molecular Biology Institute –
IBMC, Porto, Portugal), respectively.
Preparation of chitosan-coated poly(lactic-co-glycolic
acid) nanoparticles containing ferulic acid
(NP-PLGA-CS-FA)
NP-PLGA-CS-FA was obtained by a single-emulsion solvent
evaporation technique, according to a methodology proposed
by our group [14], with some modifications. Initially, 50mg of
PLGA and 10mg of FA were dissolved in 2mL of a mixture of
ethanol and dichloromethane, compounding the organic
phase. The aqueous phase consisted of 10mL of CS solution
(0.16%, w/v) and polyvinyl alcohol (PVA, 1%, w/v), both pre-
pared in 2% acetic acid (v/v). The organic phase was then
poured into the aqueous phase, and sonicated for 5min (ultra-
sonic probe QR1000, Eco-Sonic, Indaiatuba, SP, Brazil) to obtain
an oil-in-water emulsion. Subsequently, the organic solvent
was evaporated in a rotatory evaporator (TE 120 – Tecnal,
Piracicaba, SP, Brazil) under vacuum at 37 C (15min). The
nanoparticles were recovered by ultracentrifugation (20,635 g,
20 C, 45min; Z36HK Centrifuge, Hermle Wehingen, BH,
Germany) and suspended in cryoprotectant sucrose (15%; w/v).
After, the resulting suspension was frozen at –18 C and lyophi-
lized (Terroni, Brazil). Unloaded nanoparticles (blank) (NP-B)
were similarly obtained, but without FA.
Physicochemical characterization of chitosan-coated
poly(lactic-co-glycolic acid) nanoparticles containing
ferulic acid (NP-PLGA-CS-FA)
The determination of the mean diameter and the polydisper-
sity index (PDI) was performed by Dynamic Light
Scattering (DLS) (BIC 90 plus, Brookhaven Instruments Corp.,
Holtsville, NY).
The zeta potential of nanoparticles was determined by the
Laser Doppler Anemometry, based on the electrophoretic
mobility (Zetasizer ZS, Malvern, UK).
The morphology of nanoparticles was examined by scan-
ning electronmicroscopy equipped with a field emission gun
(FEG-SEM) (MIRA3 LM, Tescan, Czech Republic).
The percentage of encapsulation efficiency (%EE) was per-
formed indirectly. After the nanoparticles ultracentrifugation,
the supernatant containing non-entrapped FA was analysed
by HPLC, according to our previously validated methodology
[15], using a Waters 2695 Alliance HPLC (Waters Corporation,
Milford, MA). The %EE was determined for at least three repli-
cates, according to Equation (1).
%EE ¼ ðinitial drug amount recovered drug
=initial drug amountÞ  100 (1)
In vitro FA release assay in simulated gastric fluid,
simulated intestinal fluid and phosphate buffered
saline pH 7.4
Nanoparticles containing about 80 lg of FA were dispersed in
1mL of simulated gastric fluid (SGF – 50mM KCl, pH 1.2) and
stirred in an orbital shaker (150 rpm, 37 C). After predeter-
mined times (0.5, 1 and 2 h), the suspensions were centri-
fuged (20,635g, 20 C, 15min) and the supernatant was
collected for further HPLC analysis. The precipitate was resus-
pended in the same amount of fresh medium and nanopar-
ticles returned to stirring. After centrifugation and collection
of the supernatant in 2 h, the precipitate was suspended in
1mL of simulated intestinal fluid (SIF – 50mM KH2PO4,
15mM NaOH, 1.0% (w/v) pancreatin; pH 6.5) and agitated for
further 4 h, with sampling intervals and replacement of intes-
tinal medium at 3, 4, 5 and 6 h (relative to total test time).
The assay was performed under sink conditions.
Release assay was also performed in phosphate buffered
saline (PBS, 50mM, pH 7.4) containing tween 80 (1%, m/v).
Nanoparticles containing about 80 lg of FA were dispersed in
1mL PBS and stirred for a total period of 120 h. The ultracen-
trifugation and sampling of the supernatants occurred in the
periods of 0.5; 2; 4; 8; 24; 48; 72, 96 and 120 h. The release
profile data were analysed by mathematical studies according
to zero order, first order, second order, Higuchi and
Korsmeyer–Peppas models [16].
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Hypochlorous acid (HOCl) scavenging assay
The antioxidant activity of nanoparticles was evaluated by
the hypochlorous acid (HOCl) inhibition, which was prepared
immediately before use, from sodium hypochlorite solution
and basified water (pH 12.0). HOCl concentration was verified
spectrophotometrically at 292 nm (e292nm¼ 350M1 cm1).
Samples of free FA, NP-PLGA-CS-FA (0.5, 1.0, 2.0 and 2.5lg/
mL FA) and NP-B, diluted in phosphate buffer (50mM, pH
7.4) and incubated at 37 C and 150 rpm at periods of 0, 24,
48 and 96 h, were added to the HOCl (50 lM). After 15min,
20 mL of 10mmol/L 3,3',5,5'-tetramethylbenzidine solution
(TMB) was added, dissolved in 50% dimethylformamide,
potassium iodide (100mmol/L) and acetic acid (400mmol/L).
Then, after 5min, the absorbance was measured at 650 nm in
a microplate reader (Spectra Max 190, Molecular Devices,
Sunnyvale, CA). The solution of phosphate buffer was consid-
ered as control. The assay was performed in triplicate. The
antioxidant activity was determined as a percentage of inhib-
ition, according to Equation (2):
% Inhibition ¼ ðAbs control  Abs test=Abs controlÞ  100
(2)
Cytotoxicity assays
Cell culture
B16-F10 (ATCC CRL-6475) and HeLa (ATCC CCL-2) were cul-
tured in Iscove's modified Dulbecco's medium supplemented
with penicillin (10,000U/mL), streptomycin (10mg/mL) and
10% (v/v) of fetal bovine serum. Cells used in the intestinal
permeability study, Caco-2, HT29-MTX and Raji B, were cul-
tured in Dulbecco’s modified Eagle medium (DMEM) and sup-
plemented with 10% (v/v) of fetal bovine serum, 1% (v/v)
penicillin (100U/mL), streptomycin (100 lg/mL) and 1% (v/v)
non-essential amino acids (NEAA). All cells were maintained
in a water-saturated atmosphere, at 37 C and 5% CO2.
Cytotoxicity over HeLa and B16-F10 tumour cells lines
The cytotoxicity of the nanoparticles was evaluated by the
MTT quantitative colorimetric method, in tumour cells of mel-
anoma (B16-F10) and cervical cancer cells (HeLa). Initially, cells
were seeded in 96-well plates (1 105 cells/mL) and incubated
for 24 h at 37 C and 5% CO2. After the medium was removed
and the cells were exposed to free FA or NP-PLGA-CS-FA at
final concentrations of 5, 10, 30 and 60 lg/mL of FA. Controls
containing Iscove medium, solvent (ethanol) and NP-B were
also tested. After 24 and 48 h, cells were washed with PBS (pH
7.4) and the MTT was added to the wells and the plate was
incubated for 3 h (37 C and 5% CO2). After, MTT medium was
removed and 50 lL of ethanol and 150 lL of a mixture PBS
(pH 7.4) with isopropyl alcohol (1:1) were added. The absorb-
ance of each well was read on a microplate reader (Spectra
Max 190, Molecular Devices, Sunnyvale, CA) at 570 nm. The
experiments were performed in triplicate and the cell viability
was determined by Equation (3):
Cell viability %ð Þ ¼ ðAbs samples=Abs controlÞ  100 (3)
In vitro intestinal permeability assay
The intestinal permeability was determined based on the
works of Antunes et al. [17] and Araujo et al. [18].
Monocultures of Caco-2 cells and a triple co-culture of Caco-
2:HT29-MTX:Raji B (in a ratio of 90:10 between Caco-2 and
HT29-MTX cells) were grown in 6-well Transwell TM plates
(pore diameter 3mm, polycarbonate, 4.67 cm2) (Corning Life
Sciences, Amsterdam, The Netherlands). Caco-2 and HT29-
MTX cells were seeded in Transwell cell culture inserts at final
concentration of 1 105 cells/cm2 and incubated for 14 days,
with medium replacement every 2 days. Subsequently, in
order to induce the phenotype change of Caco-2 cells in M
cells and produce a triple model co-culture, Raji B cells were
added to the basolateral chamber, at a concentration of
1 105 cells/cm2, and were incubated for more 7 days.
Then, in orbital shaking incubator (IKA KS 4000 IC Control,
Germany) at 37 C and 100 rpm, the permeability experiments
were performed in triplicate in the apical to basolateral direc-
tion in Hank's balanced salt solution (HBSS) buffer. The initial
apical concentration of FA-loaded nanoparticles was 300 lg/
mL in a final volume of 1.5mL. At predetermined times of 15,
30, 60, 120 and 180min, samples (200 mL) were collected
from the basolateral compartment and the same amount of
fresh HBSS (pH 7.4) buffer was added, to replace the with-
drawn volume. The quantification of FA in the collected sam-
ples was performed by HPLC and the integrity of the cell
monolayers was evaluated by the measurement of the transe-
pithelial electrical resistance (TEER) before, during and at the
end of permeability assay, using an EVOM epithelial voltohm-
meter equipped with chopstick electrodes (World Precision
Instruments, Sarasota, FL) [13]. The results were expressed as
permeability and TEER percentage.
Statistical analysis
Data were expressed as mean± standard deviations. One-way
analysis of variance (ANOVA) was used for the characteriza-
tion and cytotoxicity of Caco-2 cells data. For the antioxidant
and the cytotoxicity assay over B16-F10 and HeLa tumour
cells line, two-way ANOVA was used. Both with Tukey post-
test for multiple comparisons of values. For the intestinal per-
meability assay, the analysis was realized by two-way ANOVA
with Sidak post-test. Differences were considered significant
if p< .05.
Results and discussion
Preparation and characterization of NP-PLGA-CS-FA
NP-PLGA-CS-FA were efficiently obtained by the single-emul-
sion solvent evaporation method, a very efficient method for
encapsulating a wide variety of hydrophobic compounds. The
main physicochemical characteristics of nanoparticles are
shown in Table 1. It was found that the drug incorporation
into the nanoparticles did not alter the mean diameter and
PDI (p> .05), however, the addition of CS led to an increase
in these parameters (p< .05). It may be explained due to CS-
related viscosity increase, which reduces the shear stress
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during sonication of the emulsion, and then leads to an
increase in the size of the emulsion droplets [19]. Similar
results were obtained by Nafee et al. [20], which obtained CS-
modified PLGA nanoparticles and by Yuan et al. [21], which
developed PLGA-CS nanoparticles as siRNA carriers. The mean
diameter of NP-PLGA-CS-FA was about 250 nm and PDI was
0.2. For the oral administration of polymeric nanoparticles,
the particle size below 300 nm is desirable since the particles
are able to reach microcirculation by the blood capillaries or
penetrate through pores present in the surfaces and mem-
branes [22]. PDI value demonstrated a homogeneous distribu-
tion of particle sizes, since a PDI between 0.1 and 0.25
indicates a narrow distribution range. Also, NP-PLGA-CS-FA
presented a spherical or slightly oval morphology, without
agglomerates, as showed in Figure 1.
PLGA in neutral medium has negative surface potential,
attributed to the terminal carboxyl groups [23], and this
could be verified by the zeta potential of –10mV obtained in
uncoated PLGA nanoparticles. However, when the CS coating
was added, the zeta potential of the particles increased sig-
nificantly to þ32mV (p< .05). This is a consequence of the
amino groups present in this polysaccharide and suggests
that the PLGA-FA nanoparticles were adequately coated by
CS. Besides the high stability promoted by this high modulus
value, positive surface charges are attracted by the negatively
charged cell membranes, promoting adhesion and retention
of the system at the site of action and in the intestinal
epithelium, as well as increasing the absorption of the nano-
metric system [12]. The adherence to cancer cells is also
increased since most tumour cells have negatively charged
membranes [24]. In addition, the presence of CS may
decrease the absorption and interaction of nanoparticles by
phagocytes; because this absorption occurs more frequently
on hydrophobic and negatively charged surfaces [25].
The encapsulation efficiency of FA in CS-coated PLGA
nanoparticles was about 50%. The addition of the coating
also interfered with this parameter (p< .05), slightly decreas-
ing the amount of encapsulated drug. Parveen and Sahoo
[25], also observed this phenomenon when PLGA nanopar-
ticles containing paclitaxel were coated with CS and pre-
sented as a probable cause the CS hydrophilicity, which
could prevent the entrapment of the hydrophobic drug.
In vitro FA release assay in simulated gastric fluid,
simulated intestinal fluid and phosphate buffered
saline pH 7.4
In order to predict the FA release in GIT similar conditions,
nanoparticles were incubated for 2 h in SGF (pH 1.2) and after
2 h the same nanoparticles were incubated in SIF (pH 6.5),
remaining 4 h in this medium. The results are shown in
Figure 2(A). When added to SGF, CS-coated PLGA nanopar-
ticles released only about 15% of FA after 2 h-incubation. This
release may be due to the FA adsorbed on the nanoparticles
Table 1. Mean diameter, polydispersity index, zeta potential and encapsulation efficiency of FA-loaded chitosan coated PLGA
nanoparticles (NP-PLGA-CS-FA), blank nanoparticles (NP-B) and FA-loaded PLGA nanoparticles without chitosan coating (NP-
PLGA-FA).
Formulation Mean diameter (nm) Polydispersity index Zeta potential (mV) Encapsulation efficiency ± (%)
NP-PLGA-CS-FA (n¼ 10) 242 ± 19a 0.20 ± 0.03a þ32 ± 5a 50 ± 4a
NP-B (n¼ 3) 248 ± 14a 0.23 ± 0.07a þ32 ± 7a NA
NP-PLGA-FA (n¼ 3) 196 ± 4b 0.11 ± 0.02b 10 ± 1b 60 ± 3b
NA: not applicable.
a,bValues are reported as mean diameter, polydispersity index, zeta potential and encapsulation efficiency ± standard deviation
per column analysed. Same letters mean statistical equality and inequality statistics are shown for different letters (One way-
ANOVA with post-Tukey test and a¼ 0.05).
Figure 1. FEG-SEM micrographs of PLGA-CS-FA nanoparticles. Magnification of 20 kx and 50 kx.
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surface, which is rapidly released due to weak interactions
between the drug and polymer, characterizing a burst effect.
After changing the medium to SIF, only 0.5% of FA was
released from nanoparticles, after 4 h-incubation. The higher
FA release in the acid medium may also be due to the higher
CS solubility at low pHs. In acidic media, the CS amine groups
are mostly protonated leading to the CS dissolution in the
aqueous medium, decreasing the coating layers that surround
the nanoparticles, and thus allowing an increase in drug dif-
fusion by the PLGA matrix [12]. At the end of the assay,
about 15.5% of the encapsulated FA was released into the
medium. These results suggest the potential use of PLGA-CS
nanoparticles in the FA oral administration, since nanopar-
ticles could efficiently retain most part of drug content under
GIT conditions. Thus, FA-loaded PLGA-CS nanoparticles may
be absorbed by the intestinal cells, leading to an improved
FA bioavailability.
The FA release profile from NP-PLGA-CS in PBS (50mM, pH
7.4) can be seen in Figure 2(B). A biphasic release profile was
obtained, characterized by a fast release followed by a sus-
tained release. An initial drug release occurred, in which
19.15% of total FA was released in 8 h. This initial phenom-
enon is characterized by the detachment of the drug
adsorbed on the nanoparticles surface, which is weakly
bound to the polymer. After, there was a slower and pro-
longed release, characteristic of polymeric nanoparticles and
it is due to the drug diffusion from the polymeric matrix.
After 120 h, about 28% of FA was released from the nanopar-
ticles. Similar results were obtained by other authors.
Chronopoulou et al. [12] showed a very slow and sustained
Figure 2. Release profile of FA from PLGA-CS nanoparticles in: (A) simulated gastric (SGF; pH 1.2) and intestinal (SIF; pH 6.8) fluids. The assay was conducted for 2 h
in SGF and for 4 h in SIF. (B) Phosphate buffered saline (PBS; 50mM, pH 7.4) containing tween 80 (1%). Results were expressed as mean ± standard deviation (n¼ 3).
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release of dexamethasone from PLGA-CS nanoparticles. They
attributed this characteristic to a strong interaction between
the drug and CS, and also to the coating property in acting
as a physical barrier to the drug diffusion. Parveen and Sahoo
[25] showed after 120 h of assay about 20% of paclitaxel was
released from CS-coated PLGA nanoparticles. It also has been
found that the addition of CS decreased the release rate of
paclitaxel. It can be assumed that the release of FA from
PLGA-CS nanoparticles did not present high values due to
the same principle of matrix protection by the CS coating,
leading to a lower diffusion of the drug.
The kinetic modelling obtained from the release data in
PBS revealed that the FA release from nanoparticles followed
the second-order model, i.e. the release is guided by two
release constants or kinetic constants, a and b. The constant
a is responsible for the rapid stage of release, related to
release of the drug located more externally in the nanopar-
ticle. And the b constant is related to the slow step, resulting
from the dissolution of the drug located more internally. For
the Korsmeyer–Peppas model, used to predict the mechanism
of drug or compound release, an n of 0.1344 was found, indi-
cating that the FA release process was regulated by the diffu-
sion process through the polymeric matrix [16,26].
Hypochlorous acid (HOCl) scavenging assay
Hypochlorous acid (HOCl) is a powerful oxidant produced by
activated neutrophils. This acid is obtained from the myelo-
peroxidase catalysed reaction, in which the H2O2 reacts with
chloride ions [27]. It is believed that HOCl is correlated with
the defense against microorganisms, but its excess can be
harmful, leading to tissue damage and diseases such as ath-
erosclerosis and cancer [28]. The results of HOCl scavenging
activity of free FA, NP-B and NP-PLGA-CS-FA were expressed
as percentage of HOCl inhibition and are presented in
Table 2. Significant differences were observed for the concen-
tration factor, for the group factor (free FA, NP-PLGA-CS-FA
and NP-B) and for the interaction between them, in all
times analysed.
Free FA showed a concentration-dependent antioxidant
activity. At 0 h, HOCl was inhibited using the highest concen-
tration and the antioxidant activity was maintained during all
the assay. This high antioxidant activity was expected, since
FA has already been used in cosmetic products to retard and
prevent cell aging and as a photoprotector [29]. Besides,
many studies report its outstanding antioxidant properties,
including their relation to anticarcinogenic and chemopreven-
tive [30], antibacterial [31], antifungal [32] and neuroprotec-
tive effects [33,34]. The ability of FA to form a phenoxy
radical stabilized by resonance is that allows its action and
used as an antioxidant. Moreover, NP-B also presented a
slight antioxidant activity during all experiment and it is
probably due to CS coating of nanoparticles, since its antioxi-
dant properties have been reported [3,35].
The results of HOCl inhibition by NP-PLGA-CS-FA show
that until 48 h of assay, the antioxidant activity was lower
than free FA (p< .05). This is due to the slow and sustained
FA release, as demonstrated in the in vitro release assay. In
96 h of assay, in the highest sample concentration, the
antioxidant activity of NP-PLGA-CS-FA was similar to that of
free FA (p> .05). It may be assumed that the antioxidant
activity achieved by NP-PLGA-CS-FA is a sum of the inhibi-
tions caused by the FA released and by the CS present in
nanoparticles. This phenomenon explains how a high inhib-
ition of HOCl was obtained from NP-PLGA-CS-FA, whereas in
the in vitro release profile in PBS only 25% of FA was released
within 96 h.
The results show that FA encapsulation in PLGA nanopar-
ticles coated with CS did not inhibit its high antioxidant activ-
ity. Moreover, the CS coating increased the potential use of
the system as an antioxidant. In addition, the slow, cumula-
tive and prolonged FA release in the medium decreases it
metabolism prior to its pharmacological action. These charac-
teristics, associated with pharmacokinetic advantages of
nanoparticles, demonstrate that nanoparticles may have an
even more promising antioxidant effect than free FA.
Cytotoxicity assays
Cytotoxicity over HeLa and B16-F10 tumour cells lines
One of the therapeutic properties of phenolic compounds,
such as FA, is their antitumour activity, acting in the proc-
esses of initiation, promotion and progression of tumours
[36]. FA, in particular, can inhibit the development of tumours
by capturing ROS, or for its involvement in the cell cycle by
cellular uptake [37]. In this study, the determination of the
cytotoxic activity of free FA, NP-PLGA-CS-FA and NP-B over
B16-F10 and HeLa tumour cells was evaluated for a period of
48 h. Furthermore, tests with solvents were also performed,
and these showed, at all times, cell viabilities around 100%,
confirming their non-interference in the obtained data. The
results were expressed as a percentage of cell viability and
are presented in Figure 3.
Table 2. Percentage of hypochlorous acid (HOCl) inhibition by free ferulic acid
(FA), FA-loaded chitosan-coated PLGA nanoparticles (NP-PLGA-CS-FA) and blank
nanoparticles (NP-B), in 0, 24, 48 and 96 h.
HOCl inhibition (%)
Concentration (mg/mL) FA NP-PLGA-CS-FA NP-B
0 h
0.5 27 ± 13a 15 ± 9a 28 ± 6a
1.0 61 ± 7a 42 ± 4b 28 ± 12c
2.0 90 ± 3a 32 ± 8b 31 ± 6b
2.5 93 ± 2a 45 ± 5b 27 ± 11b
24 h
0.5 24 ± 7a 26 ± 8a 15 ± 7a
1.0 68 ± 10a 40 ± 9b 17 ± 9c
2.0 93 ± 3a 54 ± 12b 27 ± 7c
2.5 94 ± 5a 65 ± 1b 29 ± 13c
48 h
0.5 24 ± 5a 25 ± 8a 9 ± 13a
1.0 33 ± 7a,b 46 ± 10a 10 ± 13b
2.0 85 ± 7a 51 ± 8b 6 ± 7c
2.5 97 ± 1a 52 ± 13b 12 ± 10c
96 h
0.5 37 ± 2a,b 21 ± 11a 39 ± 2b
1.0 67 ± 13a 32 ± 27b 26 ± 11b
2.0 75 ± 8a 33 ± 12b 34 ± 12b
2.5 89 ± 1a 69 ± 9a 29 ± 9b
a,b,cPercent inhibition of hypochlorous acid ± standard deviation per line ana-
lysed. Same letters mean statistical equality and inequality statistics are
shown for different letters (two-way ANOVA with post-Tukey test and
a¼ 0.05) (n¼ 3).
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At 24 h period, for the assays with B16-F10 cell line, in the
concentrations of 5, 10 and 30 lg/mL, there was no statistical
difference (p> .05) between the antitumour activity obtained
by the free FA and the NP-PLGA-CS-FA. Moreover, this activity
was very discreet, exhibiting a minimum cellular viability of
74%. However, at the concentration of 60 lg/mL, free FA pre-
sented higher activity than NP-PLGA-CS-FA, since their cellular
viabilities were 49% and 93%, respectively. It can be due to
the slow FA release rate from nanoparticles, as evidenced by
the in vitro release assay, in which only 20% of the encapsu-
lated FA was released into the medium within 24 h. For the
test performed with HeLa tumour cells, there was no signifi-
cant difference (p> .05) between the cell viability
obtained by FA and FA-loaded nanoparticles, at all tested
concentrations.
At 48 h, the inhibitions of both B16-F10 and HeLa cells
were increased, and for all concentrations there was no sig-
nificant difference (p> .05) between FA in solution and NP-
PLGA-CS-FA. The concentration factor presented differences
for the B16-F10 cell line (p< .05) and absence of significant
differences for the HeLa cell line (p> .05). For the B16-F10
cell line, the lowest viability occurred at the concentration of
60 lg/mL, being 46% for free FA and 37% for FA nanopar-
ticles. While for HeLa cells, the antitumour activity was lower,
suggesting that the action of FA over B16-F10 cells is more
effective. The cell viability of HeLa cells reached a minimum
of 52% using a concentration of 30 lg/mL for the NP-PLGA-
CS-FA. The results presented in the tests with both tumour
cell lines were promising, since they demonstrate that the
nanoencapsulation of FA did not inhibit the antitumour activ-
ity of FA.
Moreover, at 24 and 48 h, NP-B presented a cell viability
between 70 and 80% for B16-F10 cells and 75 and 60% for
HeLa (data not shown), indicating that the nanoparticles per
se exert some cytotoxic activity. For this reason, although the
FA release from the nanoparticles occurs in a slow and pro-
longed way, the cellular inhibition was similar to that
achieved by the isolated drug in the short period of 48 h,
since the antitumour activity of the nanoparticles does not
come only from the drug, but also from the carrier system.
The cytotoxic activity of nanoparticles without FA maybe pos-
sibly due to the presence of CS [38–40]. It is reported that
the antitumour activity of CS is due to inductive activities of
apoptosis and membrane rupture [39].
Figure 3. Effect of free ferulic acid (FA) and PLGA-CS-FA nanoparticles on the viability of (A) B16-F10 and (B) HeLa cell lines. Results were expressed as mean ± stan-
dard deviation (n¼ 3). (a, b, c) Data analysed by concentration. Same letters mean equality statistics and different letters inequality statistics (Two-way ANOVA with
post-Tukey test and a< 0.05).
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We can hypothesize that the in vivo application of NP-
PLGA-CS-FA can bring different and potentially higher results,
since nanoparticles improve the biopharmaceutical and phar-
macokinetic parameters faced by the FA, increasing its half-
life time and consequently its bioavailability. The encapsula-
tion of antitumour drugs can also lead to a tumour-specific
release, increasing the permeability and retention of these
agents due to the Enhanced Permeability and Retention
Effect (EPR).
In vitro intestinal permeability assay
In order to select drugs and evaluate their intestinal absorp-
tion potential, many in vitro models have been studied and
used [41]. These models present advantages when compared
to the in vivo tests of intestinal permeability, since besides
being less laborious and with lower costs, they also present
benefits on ethical issues [42]. In this assay, the assessment of
intestinal permeability of NP-PLGA-CS-FA was performed and
compared in two different cell models, Caco-2 cell monolayer
and triple co-culture of Caco-2/HT29-MTX/Raji B cell mono-
layer. This last intestinal monolayer model is more similar to
in vivo conditions than Caco-2 cell monolayer, as it presents
enterocytes (Caco-2 cells), the mucus-producing goblet cells
(HT29-MTX) in physiological proportions (90:10) and the
induction of M cells by Raji B [13,43,44].
Figure 4 shows the cumulative amount of permeated FA
from nanoparticles and the TEER values obtained, both
expressed as percentage, for the Caco-2 monolayer and for
the triple co-culture of Caco-2/HT29-MTX/Raji B. The FA per-
meation reached a maximum of 20% through the triple co-
culture and 5% through Caco-2 cells. This result is due to the
slow and sustained release of FA from the NP-PLGA-CS, since
according to in vitro release assay about 17% of FA was
released in PBS within 180min. Araujo et al. [13] also
obtained a lower permeability of GLP-1 when it was encapsu-
lated in nanoparticles composed of PLGA, Witepsol E85 lipid
or porous silicone, and authors related this fact to the sus-
tained drug release pattern from these nanoparticles. It was
also observed that the permeability of the encapsulated FA
was higher in the triple co-culture model than in the mono-
layer Caco-2 model (p< .05). The presence of mucus pro-
duced by HT29-MTX cells, composed largely of negatively
charged glycoproteins [45], is mainly responsible for this
increased permeability. The CS present in the coating of the
nanoparticles, due to its positively charged surface, presents
mucoadhesive properties, allowing a greater contact of the
nanoparticles with the intestinal epithelium [13,17,43–46].
Thus, there is an increase in drug concentration at the site of
absorption and a higher para- or transcellular permeation of
it. In addition, the presence of M cells in the Caco-2/HT29-
MTX/Raji B triple co-culture model, may also enable an
increase in cell permeability, since these cells are specialized
in the uptake of microorganisms and antigens, and can act as
a gateway for intestinal absorption of proteins and nanopar-
ticles [13,43].
Regarding TEER values, a slight decrease in the values was
observed before and after the permeability test, reaching a
minimum of 31% below the initial value, a result of the open-
ing of cellular tight junctions [47]. However, there was no sig-
nificant difference (p> .05) between TEER percentages
obtained for the free and encapsulated FA and between the
two models, thus demonstrating the similar integrity of the
cell monolayers.
Conclusions
NP-PLGA-CS-FA were efficiently obtained by the single-emul-
sion solvent evaporation technique and presented suitable
physicochemical characteristics for the transport of FA. The
mean diameter was below 300 nm, and the zeta potential
presented positive and far from neutrality, due to the pres-
ence of CS in the coating of the particles. The encapsulation
process allowed the sustained release of this compound,
being this release regulated by the diffusion process. The
antioxidant and cytotoxic activities of FA were confirmed and
maintained after its encapsulation, being these activities pos-
sibly the result of combined action of FA and CS. Moreover,
the nanoparticles maintained their stability in simulated gas-
tric and intestinal fluids, demonstrating resistance to the pH
Figure 4. Cumulative ferulic acid (FA) permeation and TEER cell monolayer measurements across monolayers of Caco-2 and Caco-2/HT29-MTX/Raji B triple co-cul-
ture. Results were expressed as mean ± standard deviation (n¼ 3).
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changes and avoiding the premature FA release. And finally,
the intestinal permeability of NP-PLGA-CS-FA was more prom-
inent in the presence of mucus and M cells, mainly due to
the presence of the mucoadhesive CS-coating. Thus, the
developed PLGA-CS nanoparticles are shown to be promising
carriers for the controlled release of FA from oral
administration.
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